Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Ruxolitinib + Methylprednisolone for aGVHD
NCT04397367Phase 2Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Chinese PLA General Hospital. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04397367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04397367.